ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can help prevent the cancer from coming back in patients who are ctDNA-positive or who have evidence of cancer after treatment and surgery.

Trial Details

NCT ID
NCT06902272
Phase
PHASE2
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
  • Pembrolizumab
  • Platinum Doublet Chemotherapy
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Eligible participants must be males or females ≥18 years of age on day of signing the informed consent form.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
  • Participants with histologically confirmed Stage IB (≥4 cm), II, or IIIB (N2) NSCLC (as per the 8th American Joint Committee on Cancer (AJCC)) who …
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →